Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review
- PMID: 31744346
- DOI: 10.1080/14767058.2019.1685965
Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review
Abstract
Background: Intrahepatic cholestasis of pregnancy (ICP) is characterized by the elevation of total bile acids (TBAs). The primary concern in women with ICP is the increased risk of stillbirth. ICP is generally considered as "mild" when TBA levels range from 10 to 39 µmol/L and "severe" with levels greater than 40 µmol/L, although levels of TBA ≥100 µmol/L have been also considered as a further threshold of severity.
Objective: To quantify the association between different severities of ICP (TBA 10-39, 40-99, and ≥100 µmol/L) and perinatal death.
Data sources: Medline, Embase, Scopus, Web of Sciences, and ClinicalTrial.gov were searched from the inception of each database to February 2019.
Methods of study selection: Randomized, cohort, case-control, or case series studies reporting maternal and perinatal outcomes on women with ICP by the three prespecified TBA levels (10-39, 40-99, and ≥100 µmol/L) were included. We excluded multiple gestations and trials which included an intervention. The analysis was performed with Pearson chi-square and Fisher's exact test as appropriate. Continuous outcomes were compared using metaregression with inverse variance weighting using reported sample sizes and standard deviations. Pairwise comparisons used a Bonferroni correction to control for multiple testing.
Tabulation, integration, and results: Six articles including 1280 singleton pregnancies affected by ICP were included in the systematic review. Out of the 1280 singleton pregnancies affected by ICP included, 118 had ICP with TBA ≥100 µmol/L. Perinatal death was more common in women with TBA ≥100 µmol/L (0.4% for TBA 10-39 μmol/L versus 0.3% for TBA 40-99 μmol/L versus 6.8% for TBA ≥ 100 μmol/L, p < .0001). Of the 8 perinatal deaths in the TBA ≥100 µmol/L group, 3 occurred ≥34 weeks. TBA ≥100 µmol/L increased the risk of spontaneous preterm birth (PTB) (5.4% versus 8.6% versus 18.2% respectively, p < .0001) and iatrogenic PTB (10.8% versus 21.6% versus 35.8% respectively, p<.0001) as well as meconium-stained amniotic fluid (9.0% versus 18.4% versus 31.6% respectively, p < .0001).
Conclusions: Maternal TBA ≥100 µmol/L is associated with a 6.8% incidence of perinatal death, most of which (5.9% overall) are stillbirths, while TBA <100 µmol/L are associated with an incidence of perinatal death of 0.3%. It may be reasonable to consider late preterm delivery (at about 35-36 weeks) in women with TBA ≥100 µmol/L.
Keywords: Cardiotocography; ICP; NICU; cesarean delivery; intrahepatic cholestasis of pregnancy; perinatal mortality; stillbirth.
Similar articles
-
Perinatal outcomes associated with ICP in twin pregnancies were worse than singletons: an almost 5-year retrospective cohort study.BMC Pregnancy Childbirth. 2022 Nov 5;22(1):820. doi: 10.1186/s12884-022-05160-6. BMC Pregnancy Childbirth. 2022. PMID: 36335293 Free PMC article.
-
Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.Lancet. 2019 Mar 2;393(10174):899-909. doi: 10.1016/S0140-6736(18)31877-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30773280 Free PMC article.
-
The correlation between serum total bile acid and adverse perinatal outcomes in pregnant women with intrahepatic cholestasis of pregnancy (ICP) and non-ICP hypercholanemia of pregnancy.Ann Med. 2024 Dec;56(1):2331059. doi: 10.1080/07853890.2024.2331059. Epub 2024 Mar 21. Ann Med. 2024. PMID: 38515230 Free PMC article.
-
Cholestasis: A Prospective Study of Perinatal Outcomes and Time to Symptom Improvement.Am J Perinatol. 2021 Apr;38(5):414-420. doi: 10.1055/s-0040-1717076. Epub 2020 Sep 24. Am J Perinatol. 2021. PMID: 32971564
-
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis.Lancet Gastroenterol Hepatol. 2021 Jul;6(7):547-558. doi: 10.1016/S2468-1253(21)00074-1. Epub 2021 Apr 27. Lancet Gastroenterol Hepatol. 2021. PMID: 33915090 Free PMC article.
Cited by
-
Prevalence, risk factors and adverse perinatal outcomes for Chinese women with intrahepatic cholestasis of pregnancy: a large cross-sectional retrospective study.Ann Med. 2022 Dec;54(1):2966-2974. doi: 10.1080/07853890.2022.2136400. Ann Med. 2022. PMID: 36271887 Free PMC article.
-
Intrahepatic Cholestasis of Pregnancy.Geburtshilfe Frauenheilkd. 2021 Aug;81(8):940-947. doi: 10.1055/a-1522-5178. Epub 2021 Aug 9. Geburtshilfe Frauenheilkd. 2021. PMID: 34393257 Free PMC article.
-
Perinatal outcomes associated with ICP in twin pregnancies were worse than singletons: an almost 5-year retrospective cohort study.BMC Pregnancy Childbirth. 2022 Nov 5;22(1):820. doi: 10.1186/s12884-022-05160-6. BMC Pregnancy Childbirth. 2022. PMID: 36335293 Free PMC article.
-
Assessment of the fetal thymic-thoracic ratio in pregnant women with intrahepatic cholestasis: a prospective case-control study.J Perinat Med. 2024 Jun 19;52(7):744-750. doi: 10.1515/jpm-2024-0191. Print 2024 Sep 25. J Perinat Med. 2024. PMID: 38887817
-
Navigating the Intrahepatic Cholestasis of Pregnancy: An Autobiographical Case Report.Cureus. 2024 Aug 13;16(8):e66770. doi: 10.7759/cureus.66770. eCollection 2024 Aug. Cureus. 2024. PMID: 39280363 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials